Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · IEX Real-Time Price · USD
890.66
-1.82 (-0.20%)
Apr 30, 2024, 4:00 PM EDT - Market closed
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 13,450 employees on December 31, 2023. The number of employees increased by 1,599 or 13.49% compared to the previous year.
Employees
13,450
Change (1Y)
1,599
Growth (1Y)
13.49%
Revenue / Employee
$975,257
Profits / Employee
$293,948
Market Cap
96.52B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
Dec 31, 2019 | 8,100 | 700 | 9.46% |
Dec 31, 2018 | 7,400 | 1,200 | 19.35% |
Dec 31, 2017 | 6,200 | 800 | 14.81% |
Dec 31, 2016 | 5,400 | 1,100 | 25.58% |
Dec 31, 2015 | 4,300 | 1,375 | 47.01% |
Dec 31, 2014 | 2,925 | 585 | 25.00% |
Dec 31, 2013 | 2,340 | 390 | 20.00% |
Dec 31, 2012 | 1,950 | 246 | 14.44% |
Dec 31, 2011 | 1,704 | 309 | 22.15% |
Dec 31, 2010 | 1,395 | 366 | 35.57% |
Dec 31, 2009 | 1,029 | 110 | 11.97% |
Dec 31, 2008 | 919 | 237 | 34.75% |
Dec 31, 2007 | 682 | 109 | 19.02% |
Dec 31, 2006 | 573 | -15 | -2.55% |
Dec 31, 2005 | 588 | -142 | -19.45% |
Dec 31, 2004 | 730 | 86 | 13.35% |
Dec 31, 2003 | 644 | -25 | -3.74% |
Dec 31, 2002 | 669 | 94 | 16.35% |
Dec 31, 2001 | 575 | 84 | 17.11% |
Dec 31, 2000 | 491 | 54 | 12.36% |
Dec 31, 1999 | 437 | 66 | 17.79% |
Dec 31, 1998 | 371 | 101 | 37.41% |
Dec 31, 1997 | 270 | 27 | 11.11% |
Dec 31, 1996 | 243 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
HCA Healthcare | 310,000 |
CVS Health | 300,000 |
Medtronic | 95,000 |
Sanofi | 86,088 |
Cigna | 72,500 |
GSK | 70,212 |
Boston Scientific | 48,000 |
Bristol-Myers Squibb Company | 34,100 |
REGN News
- 1 day ago - EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases - GlobeNewsWire
- 5 days ago - INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 5 days ago - Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth - Reuters
- 6 days ago - Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO - GlobeNewsWire
- 7 days ago - Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) - GlobeNewsWire
- 12 days ago - IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 13 days ago - The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors - Business Wire
- 14 days ago - Regeneron to defend US Justice Department's complaint on drug-pricing manipulation - Reuters